INMB
INmune Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.44
+7.49%Aug 26, 2026, 11:00 UTC
INmune Bio submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel in recessive dystrophic epidermolysis bullosa, supporting a planned EU marketing authorization application in Q1 2027.
Source:Aug 7, 2026, 03:04 UTC
INmune Bio plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of Q3 or early Q4 2026.
Source:Jul 31, 2026, 11:00 UTC
INmune Bio Inc. received a research and development cash rebate of approximately $4.2 million from Australia on July 30, 2026, in addition to approximately $0.4 million from the United Kingdom in June 2026.
Source:Jul 1, 2026, 00:00 UTC
Inmune Bio, Inc. entered into a warrant inducement offer letter agreement with certain holders of its April 2024 warrants, offering a reduced exercise price of $1.40 per share for 50% of outstanding warrants in exchange for amending the maturity date of the remaining 50% of unexercised warrants, expecting aggregate proceeds of $905,957.
Jun 25, 2026, 11:55 UTC
INmune Bio Inc. announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) approved the Pediatric Investigation Plan for Ebstrocel for the treatment of Recessive Dystrophic Epidermolysis Bullosa.
Source:Jun 25, 2026, 11:00 UTC
INmune Bio Inc. received MHRA approval of a Pediatric Investigation Plan (PIP) for CORDStrom™ in the United Kingdom.
Source:Jun 23, 2026, 12:00 UTC
INmune Bio received written alignment from the UK MHRA supporting its planned 2026 Conditional Marketing Authorization application for CORDStrom in RDEB.
Source:Jun 17, 2026, 00:00 UTC
Inmune Bio, Inc. elected David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen as directors effective June 16, 2026.